Moss AJ, Oakes D, Benhorin J, Carleen E. The interaction between diltiazem and left ventricular function after myocardial infarction: Multicenter Diltiazem Post-Infarction Research Group. Circulation. 1989;80(suppl):IV102 IV106. 279. O Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberg GW, Frid DJ, Cropp AB, Anderson S, Wertheimer JH, DeMets DL. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE Trial: Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol. 1998;82:881 887. 280. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HEFT III: Vasodilator-Heart Failure Trial (V-HEFT) Study Group. Circulation. 1997;96:856 863. 281. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C,Wright TJ; MOXCON Investigators.Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in pa- tients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659 667. 282. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: theAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALLHAT Collaborative Research Group. JAMA. 2000;283:1967 1975. 283. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflamma- tory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121:289 300. 284. WheltonA. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physi- ologic foundations and clinical implications. Am J Med. 1999;106:13S 24S. Key Words: AHA Scientific Statements blood pressure coronary artery disease epidemiology hypertension secondary prevention